摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3,5-dibromo-1,6-dimethylpyrazin-2(1H)-one | 467468-99-1

中文名称
——
中文别名
——
英文名称
3,5-dibromo-1,6-dimethylpyrazin-2(1H)-one
英文别名
3,5-dibromo-1,6-dimethylpyrazin-2-one
3,5-dibromo-1,6-dimethylpyrazin-2(1H)-one化学式
CAS
467468-99-1
化学式
C6H6Br2N2O
mdl
——
分子量
281.934
InChiKey
JZENMCOTMLDYJO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    120 °C
  • 沸点:
    272.0±50.0 °C(Predicted)
  • 密度:
    2.06±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    11
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    32.7
  • 氢给体数:
    0
  • 氢受体数:
    2

SDS

SDS:ea5745c5585c9988a7e2669ed9fa8ebd
查看

反应信息

  • 作为反应物:
    描述:
    3,5-dibromo-1,6-dimethylpyrazin-2(1H)-oneD(+)-10-樟脑磺酸caesium carbonate乙酸乙酯copper(l) chloride 作用下, 以 异丙醇甲苯 为溶剂, 反应 48.0h, 生成 3-(4-Chloro-phenylamino)-5-(2,4-dimethyl-phenylsulfanyl)-1,6-dimethyl-1H-pyrazin-2-one
    参考文献:
    名称:
    Design, Synthesis, and SAR of a Novel Pyrazinone Series with Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitory Activity
    摘要:
    A series of novel pyrazinones designed as non-nucleoside reverse transcriptase inhibitors (NNRTIs) was synthesized and their anti-HIV structure-activity relationship (SAR) was studied.
    DOI:
    10.1021/jm040829e
  • 作为产物:
    描述:
    2-(methylamino)propionitrile hydrobromide草酰溴N,N-二甲基甲酰胺 silica gel 、 乙酸乙酯二氯甲烷 作用下, 以 二氯甲烷 为溶剂, 反应 24.0h, 以yielding 3.90 g (69%) of 3,5-dibromo-1,6-dimethyl-2(1H)-pyrazinone (interm. 1; m.p. 119-120° C.)的产率得到3,5-dibromo-1,6-dimethylpyrazin-2(1H)-one
    参考文献:
    名称:
    Hiv inhibiting pyrazinone derivatives
    摘要:
    本发明涉及一种式1a的化合物N-氧化物,其为药学上可接受的加合物盐,季铵盐及其立体化异构形式,其中R1为氢、羟基、氰基、氨基、单或二(C1-4烷基)氨基、甲酰基、羧基、C1-6烷基、羟基C1-6烷基、多卤C1-6烷基、C2-6烯基、C2-6炔基、C3-7环烷基、C1-6烷氧基、C1-6烷基羰基、氨基羰基、S(═O)m—NH2、单或二(C1-4烷基)氨基羰基、C1-6烷氧羰基、C1-6烷基羰氧基、芳基、芳基C1-6烷基或芳氧基;R2为氢、卤素、巯基、甲酰基、氰基、羧基、偶氮基、羟基、环氧基、氨基、单或二(C1-4烷基)氨基、甲酰氨基、R5R6N—C(═O)—、R7—N═C(R8)—、C1-6烷基-S(═O)m、芳基-S(═O)m、可选择取代的C2-6烯基、可选择取代的C2-6炔基、C1-6烷氧基、羟基C1-6烷氧基、氨基C1-6烷氧基、单或二(C1-4烷基)氨基-C1-6烷氧基、C1-6烷基羰基、芳基羰基、Het1羰基、C1-6烷氧羰基、C1-6烷基羰氧基、芳基、芳氧基、芳基C1-6烷氧基、芳硫基、芳基C1-6烷硫基、单或二(芳基)氨基、Het1、Het1氧基、Het1硫基、Het1C1-6烷氧基、Het1C1-6烷硫基、单或二(Het1)氨基、C3-7环烷基、C3-7环烷氧基、C3-7环烷硫基、C1-6烷硫基、羟基C1-6烷硫基、氨基C1-6烷硫基、单或二(C1-4烷基)氨基C1-6烷硫基、可选择取代的C1-6烷基;R3或R4各自独立地表示可选择取代的苯基、吡啶基、嘧啶基、吡嗪基或吡啶嗪基;—X—为从—NR14—、—NH—NH—、—N═N—、—O—、—C1-6烷基二元基、—C(═O)—、—CHOH—、—S—、—S(═O)m-中选择的二价基团;芳基为可选择取代的苯基;Het1、Het2或Het3表示可选择取代的单环或双环杂环;本发明还涉及其作为药物的使用、其制备方法以及包含它们的制药组合物。
    公开号:
    US20040102456A1
点击查看最新优质反应信息

文献信息

  • Hiv inhibiting pyrazinone derivatives
    申请人:——
    公开号:US20040102456A1
    公开(公告)日:2004-05-27
    This invention concerns a compound of formula 1 a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein R 1 is hydrogen, hydroxy, cyano, amino, mono-or di(C 1-4 alkyl)amino, formyl, carboxyl, C 1-6 alkyl, hydroxyC 1-6 alkyl, polyhaloC 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, C 1-6 alkyloxy, C 1-6 alkylcarbonyl, aminocarbonyl, S(═O) m —NH 2 , mono-or di(C 1-4 alkyl)aminocarbonyl, C 1-6 alkyloxycarbonyl, C 1-6 alkylcarbonyloxy, aryl, arylC 1-6 alkyl or aryloxy; R 2 is hydrogen; halo; mercapto; formyl; cyano; carboxy; azido; hydroxy; oxiranyl; amino; mono- or di(C 1-4 alkyl)amino; formylamino; R 5 R 6 N—C(═O)—; R 7 —N═C(R 8 )—; C 1-6 alkyl-S(═O)m; aryl-S(═O) m ; optionally substituted C 2-6 alkenyl; optionally substituted C 2-6 alkynyl; C 1-6 alkyloxy; hydroxyC 1-6 alkyloxy; aminoC 1-6 alkyloxy; mono- or di(C 1-4 alkyl)amino-C 1-6 alkyloxy; C 1-6 alkylcarbonyl; arylcarbonyl; Het 1 carbonyl; C 1-6 alkyloxycarbonyl; C 1-6 alkylcarbonyloxy; aryl; aryloxy; arylC 1-6 alkyloxy; arylthio; arylC 1-6 alkylthio; mono- or di(aryl)amino; Het 1 ; Het 1 oxy; Het 1 thio; Het 1 C 1-6 alkyloxy; Het 1 C 1-6 alkylthio; mono- or di(Het 1 )amino; C 3-7 cycloalkyl; C 3-7 cycloalkyloxy; C 3-7 cycloalkylthio; C 1-6 alkylthio; hydroxyC 1-6 alkylthio; aminoC 1-6 alkylthio; mono- or di(C 1-4 alkyl)aminoC 1-6 alkylthio; optionally substituted C 1-6 alkyl; R 3 or R 4 each independently represent optionally be substituted phenyl, pyridyl, pyrimidinyl, pyrazinyl or pyridazinyl; —X— is a bivalent radical selected from —NR 14 —, —NH—NH—, —N═N—, —O—, —C 1-6 alkanediyl-, —C(═O)—, —CHOH—, —S—, —S(═O) m -; aryl is optionally substituted phenyl; Het 1 , Het 2 or Het 3 represent an optionally substituted monocyclic or bicyclic heterocycle; their use as a medicine, their processes for preparation and pharmaceutical compositions comprising them.
    本发明涉及一种式1a的化合物N-氧化物,其为药学上可接受的加合物盐,季铵盐及其立体化异构形式,其中R1为氢、羟基、氰基、氨基、单或二(C1-4烷基)氨基、甲酰基、羧基、C1-6烷基、羟基C1-6烷基、多卤C1-6烷基、C2-6烯基、C2-6炔基、C3-7环烷基、C1-6烷氧基、C1-6烷基羰基、氨基羰基、S(═O)m—NH2、单或二(C1-4烷基)氨基羰基、C1-6烷氧羰基、C1-6烷基羰氧基、芳基、芳基C1-6烷基或芳氧基;R2为氢、卤素、巯基、甲酰基、氰基、羧基、偶氮基、羟基、环氧基、氨基、单或二(C1-4烷基)氨基、甲酰氨基、R5R6N—C(═O)—、R7—N═C(R8)—、C1-6烷基-S(═O)m、芳基-S(═O)m、可选择取代的C2-6烯基、可选择取代的C2-6炔基、C1-6烷氧基、羟基C1-6烷氧基、氨基C1-6烷氧基、单或二(C1-4烷基)氨基-C1-6烷氧基、C1-6烷基羰基、芳基羰基、Het1羰基、C1-6烷氧羰基、C1-6烷基羰氧基、芳基、芳氧基、芳基C1-6烷氧基、芳硫基、芳基C1-6烷硫基、单或二(芳基)氨基、Het1、Het1氧基、Het1硫基、Het1C1-6烷氧基、Het1C1-6烷硫基、单或二(Het1)氨基、C3-7环烷基、C3-7环烷氧基、C3-7环烷硫基、C1-6烷硫基、羟基C1-6烷硫基、氨基C1-6烷硫基、单或二(C1-4烷基)氨基C1-6烷硫基、可选择取代的C1-6烷基;R3或R4各自独立地表示可选择取代的苯基、吡啶基、嘧啶基、吡嗪基或吡啶嗪基;—X—为从—NR14—、—NH—NH—、—N═N—、—O—、—C1-6烷基二元基、—C(═O)—、—CHOH—、—S—、—S(═O)m-中选择的二价基团;芳基为可选择取代的苯基;Het1、Het2或Het3表示可选择取代的单环或双环杂环;本发明还涉及其作为药物的使用、其制备方法以及包含它们的制药组合物。
  • HIV INHIBITING PYRAZINONE DERIVATIVES
    申请人:JANSSEN PHARMACEUTICA N.V.
    公开号:EP1370265A1
    公开(公告)日:2003-12-17
  • US7105522B2
    申请人:——
    公开号:US7105522B2
    公开(公告)日:2006-09-12
  • [EN] HIV INHIBITING PYRAZINONE DERIVATIVES<br/>[FR] DERIVES DE PYRAZINONE DESTINES A INHIBER LE VIH
    申请人:JANSSEN PHARMACEUTICA NV
    公开号:WO2002078708A1
    公开(公告)日:2002-10-10
    This invention concerns compounds of formula (I) a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein R1-4 and X are as defined in the claims; their use as a medicine for inhibiting HIV replication, their processes for preparation and pharmaceutical compositions comprising them.
  • Design, Synthesis, and SAR of a Novel Pyrazinone Series with Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitory Activity
    作者:Jan Heeres、Marc R. de Jonge、Lucien M. H. Koymans、Frits F. D. Daeyaert、Maarten Vinkers、Koen J. A. Van Aken、Eddy Arnold、Kalyan Das、Amuri Kilonda、Georges J. Hoornaert、Frans Compernolle、Marek Cegla、Rasha A. Azzam、Koen Andries、Marie-Pierre de Béthune、Hilde Azijn、Rudi Pauwels、Paul J. Lewi、Paul A. J. Janssen
    DOI:10.1021/jm040829e
    日期:2005.3.1
    A series of novel pyrazinones designed as non-nucleoside reverse transcriptase inhibitors (NNRTIs) was synthesized and their anti-HIV structure-activity relationship (SAR) was studied.
查看更多